RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells

Leukemia

Volumn 22, Issue 6, 2008, Pages 1131-1138

  Futami, M ^a   Hatano, T ^a   Soda, Y ^a   Kobayashi, S ^a   Miyagishi, M ^b   Tojo, A ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; IMATINIB; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE B; PROTEIN P190; SHORT HAIRPIN RNA; STAT5 PROTEIN; TANESPIMYCIN; VIRUS VECTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENTIATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 45149130151     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.60     Document Type: Article

References (35)

1. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079-1082.
2. Melo JV. The diversity of BCR-ABL fusion proteins and their. relationship to leukemia phenotype. Blood 1996; 88: 2375-2384.
3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561-566.
4. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005; 7: 129-141.
5. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661.
6. von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (ST1571, Glivec): A targeted oncoprotein strikes back. Leukemia 2003; 17: 829-838.
7. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105 2640-2653.
8. Soda Y, Tani K, Bai Y, Saiki M, Chen M, Izawa K et al. A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2004; 104: 356-363.
9. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
10. Hannon GJ. RNA interference. Nature 2002; 418: 244-251.
11. Wilda M, Fuchs U, Wossmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 2002; 21: 5716-5724.
12. Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J et al. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 2003; 102: 2236-2239.
13. Li MJ, McMahon R, Snyder DS, Yee JK, Rossi JJ. Specific killing of Ph+ chronic myeloid leukemia cells by a lentiviral vector-delivered anti-bcr/ abl small hairpin RNA. Oligonucleotides 2003; 13: 401-409.
14. Scherr M, Battmer K, Schultheis B, Ganser A, Eder M. Stable RNA interference (RNAi) as an option for anti-bcr-abl therapy. Gene Therapy 2005; 12: 12-21.
15. Wohlbold L, van der Kuip H, Moehring A, Granot G, Oren M, Vornlocher HP et al. All common p210 and p190 Bcr-abl variants can be targeted by RNA interference. Leukemia 2005; 19: 290-292.
16. Bai Y, Soda Y, Izawa K, Tanabe T, Kang X, Tojo A et al. Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector. Gene Therapy 2003; 10: 1446-1457.
17. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA. JAK/STAT, Raf/MEK/ERK, P13K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189-218.
18. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001; 61: 1799-1804.
19. Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2002; 62: 5761-5769.
20. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991; 65: 1153-1163.
21. Schwartzberg PL, Stall AM, Hardin JD, Bowdish KS, Humaran T, Boast S et al. Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations. Cell 1991; 65 1165-1175.
22. Voncken JW, van Schaick H, Kaartinen V, Deemer K, Coates T, Landing B et al. Increased neutrophil respiratory burst in bcr-null mutants. Cell 1995; 80: 719-728.
23. Harata M, Soda Y, Tani K, Ooi J, Takizawa T, Chen M et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood 2004; 104: 1442-1449.
24. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular, chaperone. Cell 1997; 90: 65-75.
25. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCR-ABL point mutants isolated from patients with imatinib mesylate resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002; 100: 3041-3044.
26. Withey JM, Harvey AJ, Crompton MR. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin. Leuk Res 2006; 30: 553-560.
27. Radujkovic A, Schad M, Topaly J, Veldwijk MR, Laufs S, Schultheis BS et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005; 19: 1198-1206.
28. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996; 13: 247-254.
29. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996; 183: 811-820.
30. Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 2006; 107: 4898-4906.
31. Scherr M, Chaturvedi A, Battmer K, Dallmann I, Schultheis B, Ganser A et al. Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 2006; 107 3279-3287.
32. Nieborowska-Skorska M, Wasik MA, Slupianek A, Salomoni P, Kitamura T, Calabretta B et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of CR/ABL and is required for leukemogenesis. J Exp Med 1999; 189: 1229-1242.
33. Sillaber C, Gesberl F, Frank DA, Sattler M, Griffin sJD. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 2000; 95: 2118-2125.
34. Wilson-Rawls J, Xie S, Liu J, Laneuville P, Arlinghaus RB. P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation. Cancer Res 1996; 56: 3426-3430.
35. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al, The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002; 21: 5766-5774.